-
公开(公告)号：US20160213776A1
公开(公告)日：2016-07-28
申请号：US15093652
申请日：2016-04-07
Applicant: GlaxoSmithKline Biologicals SA
Inventor： Manmohan SINGH , David A.G. SKIBINKSI , Tom Yao-Hsiang WU , Yongkai LI , Alex CORTEZ , Xiaoyue ZHANG , Yefen ZOU , Timothy Z. HOFFMAN , Jianfeng PAN , Kathy YUE
IPC: A61K39/39 , C07F9/6512 , C07F9/645 , C07F9/6558 , A61K39/05 , A61K39/09 , A61K39/02 , A61K39/145 , A61K39/29 , A61K39/13 , A61K39/095 , C07F9/6561 , A61K39/08
CPC classification number: A61K39/39 , A61K31/661 , A61K31/6615 , A61K31/662 , A61K39/02 , A61K39/05 , A61K39/08 , A61K39/092 , A61K39/095 , A61K39/13 , A61K39/145 , A61K39/292 , A61K2039/55505 , A61K2039/55511 , C07D471/04 , C07D487/04 , C07F9/645 , C07F9/6512 , C07F9/65583 , C07F9/6561 , C07F9/65616 , Y02A50/466
Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.
-
公开(公告)号：US20180256695A1
公开(公告)日：2018-09-13
申请号：US15975388
申请日：2018-05-09
Applicant: GlaxoSmithKline Biologicals SA
Inventor： Barbara BAUDNER , David A.G. SKIBINSKI , Manmohan SINGH , Derek O'HAGAN
IPC: A61K39/00 , A61K39/39 , A61K31/66 , A61K33/06 , A61K39/102 , A61K39/116 , A61K39/12 , A61K31/4375 , A61K39/295
CPC classification number: A61K39/0018 , A61K31/4375 , A61K31/66 , A61K33/06 , A61K39/102 , A61K39/116 , A61K39/12 , A61K39/295 , A61K39/39 , A61K2039/545 , A61K2039/55505 , A61K2039/55555 , A61K2039/55566 , A61K2039/70 , C12N2730/10134 , C12N2770/32634 , Y02A50/466 , A61K2300/00
Abstract: Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. compositions which are adjuvanted with an oil-in-water emulsion adjuvant.
-
公开(公告)号：US20180169204A1
公开(公告)日：2018-06-21
申请号：US15887203
申请日：2018-02-02
Applicant: GlaxoSmithKline Biologicals SA
Inventor： Barbara BAUDNER , David SKIBINSKI , Manmohan SINGH , Derek O'HAGAN
IPC: A61K39/00 , A61K39/12 , A61K39/102 , A61K31/4375 , A61K31/66 , A61K33/06 , A61K39/39 , A61K39/116 , A61K39/295
CPC classification number: A61K39/0018 , A61K31/4375 , A61K31/66 , A61K33/06 , A61K39/102 , A61K39/116 , A61K39/12 , A61K39/295 , A61K39/39 , A61K2039/545 , A61K2039/55505 , A61K2039/55555 , A61K2039/55566 , A61K2039/70 , C12N2730/10134 , C12N2770/32634 , Y02A50/466 , A61K2300/00
Abstract: Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. compositions which are adjuvanted with an oil-in-water emulsion adjuvant.
-
公开(公告)号：US20170080084A1
公开(公告)日：2017-03-23
申请号：US15126508
申请日：2015-03-17
Applicant: GlaxoSmithKline Biologicals SA
Inventor： Luis BRITO , Stephanie Kay DODD , Derek O'HAGAN , Manmohan SINGH
CPC classification number: A61K39/39 , A61K9/1075 , A61K39/145 , A61K47/06 , A61K47/26 , A61K2039/55566 , C12N7/00 , C12N2760/16034
Abstract: Oil-in-water emulsions with small droplet sizes can be formed without requiring either microfluidisation or heating to cause phase inversion, but rather by simple mixing of a pre-mixed composition of oil and a surfactant component comprising at least one surfactant component with aqueous material. The HLB value of the surfactant component can be selected to give a composition which, on mixing with a volume excess of aqueous material, spontaneously forms an oil in water emulsion with submicron oil droplets having a diameter
-
Patent Agency Ranking
公开(公告)号：US20180177871A1
公开(公告)日：2018-06-28
申请号：US15905483
申请日：2018-02-26
Applicant: GlaxoSmithKline Biologicals SA
Inventor： Barbara BAUDNER , Derek O'HAGAN , Manmohan SINGH , Simone BUFALI
CPC classification number: A61K39/39 , A61K9/107 , A61K39/0018 , A61K39/13 , A61K2039/55505 , A61K2039/55511 , A61K2039/55566 , A61K2039/55572 , C12N7/00 , C12N2770/32634 , Y02A50/466
Abstract: The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response.
-
公开(公告)号：US20160263216A1
公开(公告)日：2016-09-15
申请号：US15163592
申请日：2016-05-24
Applicant: GlaxoSmithKline Biologicals SA
Inventor： Barbara BAUDNER , Derek O'HAGAN , Manmohan SINGH , Simone BUFALI
CPC classification number: A61K39/39 , A61K9/107 , A61K39/0018 , A61K39/13 , A61K2039/55505 , A61K2039/55511 , A61K2039/55566 , A61K2039/55572 , C12N7/00 , C12N2770/32634 , Y02A50/466
Abstract: The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response.
-
公开(公告)号：US20160228529A1
公开(公告)日：2016-08-11
申请号：US15011216
申请日：2016-01-29
Applicant: GlaxoSmithKline Biologicals SA
Inventor： Mario CONTORNI , Jina KAZZAZ , Derek O'HAGAN , Manmohan SINGH , Mildred UGOZZOLI
IPC: A61K39/095
CPC classification number: A61K39/095 , A61K9/107 , A61K9/19 , A61K2039/55566
Abstract: A dual formulation for vaccines against Neisseria meningitidis serogroup B (‘Men-B’) comprises (i) an oil-in-water emulsion adjuvant and (ii) a Men-B immunogenic component in lyophilised form. The lyophilised Men-B antigens can be reconstituted into liquid adjuvanted form at the time of use ready for administration to a patient. This formulation has been found to give excellent result in terms of both stability and immunogenicity. The lyophilised component can also include one or more conjugated saccharides from N. meningitidis in serogroups A, C, W135 and/or Y.
Abstract translation: 针对脑膜炎奈瑟氏球菌血清群B（'Men-B'）的疫苗的双重配方包括（i）水包油乳剂佐剂和（ii）冻干形式的Men-B免疫原性组分。 冻干的Men-B抗原可以在使用时重建成液体佐剂形式，准备用于给予患者。 已经发现这种配方在稳定性和免疫原性方面都获得了优异的结果。 冻干组分还可以包含一种或多种血清群A，C，W135和/或Y中脑膜炎奈瑟氏球菌的共轭糖。
-
公开(公告)号：US20220192997A1
公开(公告)日：2022-06-23
申请号：US17683931
申请日：2022-03-01
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Andrew GEALL , Christian Walter MANDL , Derek Thomas O'HAGAN , Manmohan SINGH
IPC: A61K9/50 , A61K39/155 , A61K39/245 , C12N15/86 , C12N15/88 , A61K39/12 , A61K9/127 , A61K9/00
Abstract: Nucleic acid immunisation is achieved by delivering a self-replicating RNA encapsulated within a small particle. The RNA encodes an immunogen of interest, and the particle may deliver this RNA by mimicking the delivery function of a natural RNA virus. Thus the invention provides a non-virion particle for in vivo delivery of RNA to a vertebrate cell, wherein the particle comprises a delivery material encapsulating a self-replicating RNA molecule which encodes an immunogen. These particles are useful as components in pharmaceutical compositions for immunising subjects against various diseases.
-
公开(公告)号：US20170100472A1
公开(公告)日：2017-04-13
申请号：US15384162
申请日：2016-12-19
Applicant: GlaxoSmithKline Biologicals SA
Inventor： Barbara BAUDNER , Derek O'HAGAN , Manmohan SINGH , Simone BUFALI
IPC: A61K39/095 , A61K39/39
CPC classification number: A61K39/095 , A61K39/39 , A61K2039/55505 , A61K2039/55511 , A61K2039/55566 , A61K2039/55572 , A61K2039/6037
Abstract: Serogroup B meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“DTP”) to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type DTP ratios. The adjuvant can improve the immune response which the composition elicits; alternatively, by including an adjuvant it is possible for the compositions to have a relatively lower amount of antigen while nevertheless having immunogenicity which is comparable to unadjuvanted combination vaccines.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.017 seconds)
